You are here: Industry Insights > Agios Pharmaceuticals

News List

Servier to Acquire Agios Pharmaceuticals' Oncology Business prnasia
December 22, 2020
Servier, a global pharmaceutical company, announced that it has entered into an agreement for the acquisition of Agios Pharmaceuticals' oncology business including its commercial, clinical and research-stage oncology portfolio for up to $2 billion ...
FDA Grants Breakthrough Device Designation to Thermo Fisher’s Oncomine Precision Assay americanpharmaceuticalreview
June 24, 2020
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Thermo Fisher Scientific's Oncomine Precision Assay.
Agios, Royalty Pharma Announce Purchase Agreement for IDHIFA Royalty americanpharmaceuticalreview
June 23, 2020
Agios Pharmaceuticals has sold its tiered, sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA® (enasidenib) ...
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia americanpharmaceuticalreview
June 18, 2020
Agios Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase-R (PKR) activator mitapivat for the treatment of patients with thalassemia.
Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Rela biospace
December 28, 2017
Agios Pharmaceuticals, Inc., a leader in cellular metabolism for the treatment of cancer and rare genetic disorders, today announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA)